# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Balaji Prasad maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target ...
Truist Securities analyst Les Sulewski maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target...
Raising Full Year 2024 GuidanceThe Company is raising its previously provided full year 2024 guidance. Updated GuidancePrior Gu...
Delivers more "Good On" time with less frequent dosing compared to Immediate Release CD/LDUnderscores Amneal's lead...